Given the potential of the HER2DX ERBB2 mRNA score as a predictive biomarker, particularly in the context of THP treatment, our study aims to validate the ability of the HER2DX ERBB2 mRNA score to predict survival outcomes in patients with advanced HER2+ breast cancer treated with first-line THP. This evidence concerns the gene ERBB2 and breast cancer.